바이오엔지니어링 단백질 의약품 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 전망(2024-2034년)

Bioengineered Protein Drugs Market - Scope of Report

TMR's report on the global bioengineered protein drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bioengineered protein drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bioengineered protein drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bioengineered protein drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bioengineered protein drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bioengineered protein drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bioengineered protein drugs market.

The report delves into the competitive landscape of the global bioengineered protein drugs market. Key players operating in the global bioengineered protein drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bioengineered protein drugs market profiled in this report.

Key Questions Answered in Global bioengineered protein drugs Market Report:

• What is the sales/revenue generated by bioengineered protein drugs across all regions during the forecast period?
• What are the opportunities in the global bioengineered protein drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Bioengineered Protein Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global bioengineered protein drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global bioengineered protein drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bioengineered protein drugs market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Bioengineered Protein Drugs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Bioengineered Protein Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product /Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2020-2034
  • 6.3.1. Monoclonal Antibodies
    • 6.3.1.1. Humira
    • 6.3.1.2. Rituxan
    • 6.3.1.3. Avastin
    • 6.3.1.4. Herceptin
    • 6.3.1.5. Remicade
    • 6.3.1.6. Lucentis
    • 6.3.1.7. Enbrel
    • 6.3.1.8. Synazis
    • 6.3.1.9. Others
  • 6.3.2. Therapeutic Proteins
    • 6.3.2.1. Hormones
    • 6.3.2.2. Cytokines
      • 6.3.2.2.1. Neupogen
      • 6.3.2.2.2. Neulasta
      • 6.3.2.2.3. Interferon Alpha
      • 6.3.2.2.4. Erythropoietin Alpha
      • 6.3.2.2.5. Interleukin
      • 6.3.2.2.6. Others
  • 6.3.3. Blood Factor
  • 6.3.4. Enzyme Therapy
    • 6.3.4.1. Systemic Enzyme Therapy
    • 6.3.4.2. Digestive Enzyme Therapy
  • 6.3.5. Thrombolytics
    • 6.3.5.1. tPA
    • 6.3.5.2. Streptokinase
    • 6.3.5.3. Urokinase
  • 6.3.6. Vaccines
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Disease Condition

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Disease Condition, 2020-2034
  • 7.3.1. Cancer
  • 7.3.2. Diabetes
  • 7.3.3. Autoimmune Disorder
  • 7.3.4. Infectious Disease
  • 7.3.5. Hematopoiesis
  • 7.3.6. CVD
  • 7.3.7. Neurodegenerative
  • 7.3.8. Others
• 7.4. Market Attractiveness Analysis, by Disease Condition

8. Global Bioengineered Protein Drugs Market Analysis and Forecast, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by End-user, 2020-2034
  • 8.3.1. Pharma and Biotech Companies
  • 8.3.2. CROs
  • 8.3.3. Research Institutes
• 8.4. Market Attractiveness Analysis, by End-user

9. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Bioengineered Protein Drugs Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Drug Type, 2020-2034
  • 10.3.1. Monoclonal Antibodies
    • 10.3.1.1. Humira
    • 10.3.1.2. Rituxan
    • 10.3.1.3. Avastin
    • 10.3.1.4. Herceptin
    • 10.3.1.5. Remicade
    • 10.3.1.6. Lucentis
    • 10.3.1.7. Enbrel
    • 10.3.1.8. Synazis
    • 10.3.1.9. Others
  • 10.3.2. Therapeutic Proteins
    • 10.3.2.1. Hormones
    • 10.3.2.2. Cytokines
      • 10.3.2.2.1. Neupogen
      • 10.3.2.2.2. Neulasta
      • 10.3.2.2.3. Interferon Alpha
      • 10.3.2.2.4. Erythropoietin Alpha
      • 10.3.2.2.5. Interleukin
      • 10.3.2.2.6. Others
  • 10.3.3. Blood Factor
  • 10.3.4. Enzyme Therapy
    • 10.3.4.1. Systemic Enzyme Therapy
    • 10.3.4.2. Digestive Enzyme Therapy
  • 10.3.5. Thrombolytics
    • 10.3.5.1. tPA
    • 10.3.5.2. Streptokinase
    • 10.3.5.3. Urokinase
  • 10.3.6. Vaccines
• 10.4. Market Value Forecast, by Disease Condition, 2020-2034
  • 10.4.1. Cancer
  • 10.4.2. Diabetes
  • 10.4.3. Autoimmune Disorder
  • 10.4.4. Infectious Disease
  • 10.4.5. Hematopoiesis
  • 10.4.6. CVD
  • 10.4.7. Neurodegenerative
  • 10.4.8. Others
• 10.5. Market Value Forecast, by End-user, 2020-2034
  • 10.5.1. Pharma and Biotech Companies
  • 10.5.2. CROs
  • 10.5.3. Research Institutes
• 10.6. Market Value Forecast, by Country, 2020-2034
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Drug Type
  • 10.7.2. By Disease Condition
  • 10.7.3. By End-user
  • 10.7.4. By Country

11. Europe Bioengineered Protein Drugs Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Drug Type, 2020-2034
  • 11.3.1. Monoclonal Antibodies
    • 11.3.1.1. Humira
    • 11.3.1.2. Rituxan
    • 11.3.1.3. Avastin
    • 11.3.1.4. Herceptin
    • 11.3.1.5. Remicade
    • 11.3.1.6. Lucentis
    • 11.3.1.7. Enbrel
    • 11.3.1.8. Synazis
    • 11.3.1.9. Others
  • 11.3.2. Therapeutic Proteins
    • 11.3.2.1. Hormones
    • 11.3.2.2. Cytokines
      • 11.3.2.2.1. Neupogen
      • 11.3.2.2.2. Neulasta
      • 11.3.2.2.3. Interferon Alpha
      • 11.3.2.2.4. Erythropoietin Alpha
      • 11.3.2.2.5. Interleukin
      • 11.3.2.2.6. Others
  • 11.3.3. Blood Factor
  • 11.3.4. Enzyme Therapy
    • 11.3.4.1. Systemic Enzyme Therapy
    • 11.3.4.2. Digestive Enzyme Therapy
  • 11.3.5. Thrombolytics
    • 11.3.5.1. tPA
    • 11.3.5.2. Streptokinase
    • 11.3.5.3. Urokinase
  • 11.3.6. Vaccines
• 11.4. Market Value Forecast, by Disease Condition, 2020-2034
  • 11.4.1. Cancer
  • 11.4.2. Diabetes
  • 11.4.3. Autoimmune Disorder
  • 11.4.4. Infectious Disease
  • 11.4.5. Hematopoiesis
  • 11.4.6. CVD
  • 11.4.7. Neurodegenerative
  • 11.4.8. Others
• 11.5. Market Value Forecast, by End-user, 2020-2034
  • 11.5.1. Pharma and Biotech Companies
  • 11.5.2. CROs
  • 11.5.3. Research Institutes
• 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Type
  • 11.7.2. By Disease Condition
  • 11.7.3. By End-user
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Drug Type, 2020-2034
  • 12.3.1. Monoclonal Antibodies
    • 12.3.1.1. Humira
    • 12.3.1.2. Rituxan
    • 12.3.1.3. Avastin
    • 12.3.1.4. Herceptin
    • 12.3.1.5. Remicade
    • 12.3.1.6. Lucentis
    • 12.3.1.7. Enbrel
    • 12.3.1.8. Synazis
    • 12.3.1.9. Others
  • 12.3.2. Therapeutic Proteins
    • 12.3.2.1. Hormones
    • 12.3.2.2. Cytokines
      • 12.3.2.2.1. Neupogen
      • 12.3.2.2.2. Neulasta
      • 12.3.2.2.3. Interferon Alpha
      • 12.3.2.2.4. Erythropoietin Alpha
      • 12.3.2.2.5. Interleukin
      • 12.3.2.2.6. Others
  • 12.3.3. Blood Factor
  • 12.3.4. Enzyme Therapy
    • 12.3.4.1. Systemic Enzyme Therapy
    • 12.3.4.2. Digestive Enzyme Therapy
  • 12.3.5. Thrombolytics
    • 12.3.5.1. tPA
    • 12.3.5.2. Streptokinase
    • 12.3.5.3. Urokinase
  • 12.3.6. Vaccines
• 12.4. Market Value Forecast, by Disease Condition, 2020-2034
  • 12.4.1. Cancer
  • 12.4.2. Diabetes
  • 12.4.3. Autoimmune Disorder
  • 12.4.4. Infectious Disease
  • 12.4.5. Hematopoiesis
  • 12.4.6. CVD
  • 12.4.7. Neurodegenerative
  • 12.4.8. Others
• 12.5. Market Value Forecast, by End-user, 2020-2034
  • 12.5.1. Pharma and Biotech Companies
  • 12.5.2. CROs
  • 12.5.3. Research Institutes
• 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Type
  • 12.7.2. By Disease Condition
  • 12.7.3. By End-user
  • 12.7.4. By Country/Sub-region

13. Latin America Bioengineered Protein Drugs Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Drug Type, 2020-2034
  • 13.3.1. Monoclonal Antibodies
    • 13.3.1.1. Humira
    • 13.3.1.2. Rituxan
    • 13.3.1.3. Avastin
    • 13.3.1.4. Herceptin
    • 13.3.1.5. Remicade
    • 13.3.1.6. Lucentis
    • 13.3.1.7. Enbrel
    • 13.3.1.8. Synazis
    • 13.3.1.9. Others
  • 13.3.2. Therapeutic Proteins
    • 13.3.2.1. Hormones
    • 13.3.2.2. Cytokines
      • 13.3.2.2.1. Neupogen
      • 13.3.2.2.2. Neulasta
      • 13.3.2.2.3. Interferon Alpha
      • 13.3.2.2.4. Erythropoietin Alpha
      • 13.3.2.2.5. Interleukin
      • 13.3.2.2.6. Others
  • 13.3.3. Blood Factor
  • 13.3.4. Enzyme Therapy
    • 13.3.4.1. Systemic Enzyme Therapy
    • 13.3.4.2. Digestive Enzyme Therapy
  • 13.3.5. Thrombolytics
    • 13.3.5.1. tPA
    • 13.3.5.2. Streptokinase
    • 13.3.5.3. Urokinase
  • 13.3.6. Vaccines
• 13.4. Market Value Forecast, by Disease Condition, 2020-2034
  • 13.4.1. Cancer
  • 13.4.2. Diabetes
  • 13.4.3. Autoimmune Disorder
  • 13.4.4. Infectious Disease
  • 13.4.5. Hematopoiesis
  • 13.4.6. CVD
  • 13.4.7. Neurodegenerative
  • 13.4.8. Others
• 13.5. Market Value Forecast, by End-user, 2020-2034
  • 13.5.1. Pharma and Biotech Companies
  • 13.5.2. CROs
  • 13.5.3. Research Institutes
• 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Type
  • 13.7.2. By Disease Condition
  • 13.7.3. By End-user
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Drug Type, 2020-2034
  • 14.3.1. Monoclonal Antibodies
    • 14.3.1.1. Humira
    • 14.3.1.2. Rituxan
    • 14.3.1.3. Avastin
    • 14.3.1.4. Herceptin
    • 14.3.1.5. Remicade
    • 14.3.1.6. Lucentis
    • 14.3.1.7. Enbrel
    • 14.3.1.8. Synazis
    • 14.3.1.9. Others
  • 14.3.2. Therapeutic Proteins
    • 14.3.2.1. Hormones
    • 14.3.2.2. Cytokines
      • 14.3.2.2.1. Neupogen
      • 14.3.2.2.2. Neulasta
      • 14.3.2.2.3. Interferon Alpha
      • 14.3.2.2.4. Erythropoietin Alpha
      • 14.3.2.2.5. Interleukin
      • 14.3.2.2.6. Others
  • 14.3.3. Blood Factor
  • 14.3.4. Enzyme Therapy
    • 14.3.4.1. Systemic Enzyme Therapy
    • 14.3.4.2. Digestive Enzyme Therapy
  • 14.3.5. Thrombolytics
    • 14.3.5.1. tPA
    • 14.3.5.2. Streptokinase
    • 14.3.5.3. Urokinase
  • 14.3.6. Vaccines
• 14.4. Market Value Forecast, by Disease Condition, 2020-2034
  • 14.4.1. Cancer
  • 14.4.2. Diabetes
  • 14.4.3. Autoimmune Disorder
  • 14.4.4. Infectious Disease
  • 14.4.5. Hematopoiesis
  • 14.4.6. CVD
  • 14.4.7. Neurodegenerative
  • 14.4.8. Others
• 14.5. Market Value Forecast, by End-user, 2020-2034
  • 14.5.1. Pharma and Biotech Companies
  • 14.5.2. CROs
  • 14.5.3. Research Institutes
• 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Type
  • 14.7.2. By Disease Condition
  • 14.7.3. By End-user
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Abbott
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Amgen Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Bayer AG
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Biocon
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Dr. Reddy's Laboratories
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Lilly
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. F. Hoffmann - La Roche Ltd.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Fresenius Kabi AG
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. GSK
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Janssen Global Services
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. SWOT Analysis
    • 15.3.10.4. Financial Overview
    • 15.3.10.5. Strategic Overview
  • 15.3.11. Merck & Co., Inc.
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Product Portfolio
    • 15.3.11.3. SWOT Analysis
    • 15.3.11.4. Financial Overview
    • 15.3.11.5. Strategic Overview
  • 15.3.12. Novartis AG
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Product Portfolio
    • 15.3.12.3. SWOT Analysis
    • 15.3.12.4. Financial Overview
    • 15.3.12.5. Strategic Overview
  • 15.3.13. Panacea Biotec
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Product Portfolio
    • 15.3.13.3. SWOT Analysis
    • 15.3.13.4. Financial Overview
    • 15.3.13.5. Strategic Overview
  • 15.3.14. ProBioGen AG
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Product Portfolio
    • 15.3.14.3. SWOT Analysis
    • 15.3.14.4. Financial Overview
    • 15.3.14.5. Strategic Overview
  • 15.3.15. Reliance Life Science
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Product Portfolio
    • 15.3.15.3. SWOT Analysis
    • 15.3.15.4. Financial Overview
    • 15.3.15.5. Strategic Overview
  • 15.3.16. Sanofi
    • 15.3.16.1. Company Overview
    • 15.3.16.2. Product Portfolio
    • 15.3.16.3. SWOT Analysis
    • 15.3.16.4. Financial Overview
    • 15.3.16.5. Strategic Overview